BridgeBio Pharma, Inc. · NASDAQ:BBIO

BridgeBio Pharma — Investor Presentation (April 2025)

56 slides from BridgeBio Pharma's investor presentation, Apr 29, 2025

  1. Slide 1: Corporate Presentation

    Corporate Presentation April 29th, 2025

  2. Slide 2: Forward Looking Statements and Disclaimer

    Forward Looking Statements and Disclaimer The presentation contains forward-looking statements. Statements made or presented may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Sectio

  3. Slide 3: …is now approved in the US; EU, Japan, and UK

    …is now approved in the US …is now approved in the EU, Japan, and UK 2

  4. Slide 4: Three Phase 3 Trials are now fully enrolled

    Three Phase 3 Trials are now fully enrolled Trial enrolled 112 patients to evaluate BBP-418 in Limb-Girdle Muscular Dystrophy 2I/R9 Trial enrolled 71 patients to evaluate encaleret in Autosomal Dominant Hypocalcemia Type 1 Trial enrolled 114 participants to evaluate infigratinib in Achondroplasia 3

  5. Slide 5: BridgeBio's objective function

    BridgeBio’s objective function Patient impact… …through sustainable value creation 𝑡𝑡 𝑁𝑁 ∆𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄 (𝑖𝑖) Objective: max � � ∗ 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 (𝑖𝑖) Each program must be: 0 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝐷𝐷𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑖𝑖=1 • Based on beautiful science with a…

  6. Slide 6: BridgeBio is a new type of biopharmaceutical company

    BridgeBio is a new type of biopharmaceutical company From: To: Slow and bureaucratic decision making Rapid and decentralized decision making Expensive platforms with long lead times Assets selected to target genetic diseases before proof-of-concept data at their source High fixed costs Variablized a

  7. Slide 7: The right approach: decentralized R&D, centralized infrastructure

    The right approach: decentralized R&D, centralized infrastructure Build “minimum viable companies” to Build central infrastructure for de-risk programs as quickly and functions with economies of scale, efficiently as possible such as commercial Leverage hyper-experienced Leverage seasoned company R&

  8. Slide 8: The right space: capitalizing on a scientific revolution to treat a massive unmet need

    The right space: capitalizing on a scientific revolution to treat a massive unmet need for genetic diseases There are 10,000+ counted rare diseases affecting 450 million+ people globally Genetics ~3,000 without known molecular cause Macromolecules ~500 with approved therapies Clinical Diagnosis Ther

  9. Slide 9: Our leadership team has world-renowned drug hunters and operators

    Our leadership team has world-renowned drug hunters and operators Neil Kumar, PhD Thomas Trimarchi, PhD Christine Siu Ananth Sridhar Justin To Eric David, MD, JD Founder and President and Chief Executive Officer, Chief Operating Officer, Chief Executive Officer, Chief Executive Officer, Chief Execut

  10. Slide 10: We have built a sustainable, high velocity engine to deliver medicines

    We have built a sustainable, high velocity engine to deliver medicines Obtained Approval for 3 Medicines > 2,000 > 30 trials 3 fully patients in > 30 countries enrolled trials > 500 sites pivotal trials > 70 > 35 19 < $10M and papers academic INDs created < 3 yrs to IND published partnerships 9

  11. Slide 11: A pipeline of products that sing across the BridgeBio ecosystem

    A pipeline of products that sing across the BridgeBio ecosystem Pre- Patients Market Program Indication Phase 1 Phase 2 Phase 3 Approved Clinical (US + EU) Opportunity  Attruby Transthyretin Amyloidosis 500,000+ $20B+ (acoramidis) (ATTR-CM)  Nulibry Molybdenum Cofactor Deficiency <100 Partnered (f

  12. Slide 12: We are well-financed and expect to hit numerous milestones in 2025

    We are well-financed and expect to hit numerous milestones in 2025 1H 2025 2H 2025 • Q2 and Q3 Earnings Calls • Beyonttra: EU approval • Encaleret: LPLV, Topline • Beyonttra: Japan approval • BBP-418: LPLV, Topline • Q1 Earnings Call • Infigratinib: LPLV De-risked PYS Lives impacted vision for 20

  13. Slide 13: BridgeBio is relatively unaffected by tariffs given US IP, domicile, and manufacturing base

    BridgeBio is relatively unaffected by tariffs given US IP, domicile, and manufacturing base Unaffected by reciprocal tariffs as a biopharmaceutical company Minimal exposure to IEEPA and potential section 232 tariffs given US manufacturing base Impact to NPV is < 1% IEEPA = International Emergency Ec

  14. Slide 14: Attruby Now Approved

    Attruby n°] 7) > te} — roy 2 < S } ]2

  15. Slide 15: Attruby is now FDA Approved – Key Highlights

    Attruby is now FDA Approved – Key Highlights First and only approved product with a label specifying near-complete stabilization of TTR Effect seen as early as 3 months – the most rapid benefit seen in any Phase 3 study of ATTR-CM to date 42% reduction in composite of all-cause mortality and recurre

  16. Slide 16: Our responsibility to patients spans beyond R&D

    Our responsibility to patients spans beyond R&D – we are committed to ensuring the best access and affordability of any ATTR-CM medicine Dedicated patient support team Insurance navigation and support Ensuring easy and fast access: The least expensive ATTR treatment: Medicine shipped directly to pat

  17. Slide 17: We make it easy through simplified, differentiated, and generous access programs

    We make it easy through simplified, differentiated, and generous access programs 28-day supply for patients new to Attruby Free Trial (newly diagnosed or switching from another therapy) Distribution Independent and rare/orphan disease–focused Specialty Pharmacies (SPs) Network where Institutional SP

  18. Slide 18: Performance to date indicates strong commercial momentum

    Performance to date indicates strong commercial momentum 2,072 756 77% $36.7M Unique U.S. patient Unique U.S. Medicare lives in equal Total U.S. revenue from prescriptions for Attruby prescribing HCPs formulary position to tafamidis Q1 sales of Attruby As of April 25, 2025 Q1 2025 17

  19. Slide 19: Positive feedback all around on market access

    Positive feedback all around on market access Pricing: ForgingBridges: “ You priced responsibly and have a good label; we will have you at parity with tafamidis. Also, I have never seen a company offer free drug to their trial patients. Shows commitment.” - Payer the health system's mission of putti

  20. Slide 20: Our commercial infrastructure is deployed across the US to ensure full provider coverage

    Our commercial infrastructure is deployed across the US to ensure full provider coverage ATTR-CM Prescriber Market BridgeBio Coverage Dedicated commercial & US-field-based  team with singular focus on serving patients with ATTR-CM Salesforce is built to adequately cover  every HCP and institution

  21. Slide 21: Our Attruby team has experienced industry leaders who have built and launched blockbuster drugs

    Our Attruby team has experienced industry leaders who have built and launched blockbuster drugs Matt Outten Julie Everett John Whang Chief Commercial Officer Chief Business Officer Chief Medical Affairs Officer • Broad commercial leadership expertise with success • Successfully led cross-functional

  22. Slide 22: ATTR is a multi-billion-dollar market primed for continued expansion

    ATTR is a multi-billion-dollar market primed for continued expansion Global annual ATTR market sales1 $B $15-$202 Market growth drivers include: $6.8 • With more sponsors, there is expanding disease awareness +58% $4.3 • Increased global $3.2 adoption of non- $2.6 invasive diagnostic $1.7 tools $0.7

  23. Slide 23: Recent demand study shows significant Attruby market potential

    Recent demand study shows significant Attruby market potential vs. partial stabilizer and partial knockdown Surveyed HCPs expect 30 - 40%+ peak market share for Attruby HCP sentiment towards Attruby is positive Attruby Market Share as % of Future Competitive Market Acoramidis showed dramatic reducti

  24. Slide 24: BridgeBio is committed to advancing Attruby's scientific narrative

    BridgeBio is committed to advancing Attruby’s scientific narrative to ensure as many appropriate patients as possible can benefit 2024 2025+ ATTR-CM ATTR-CM WT and hereditary WT and hereditary Extended Ph. 3 data disclosures at Attruby lifecycle management and further ACC, ESC-HF, ESC, HFSA, and AHA

  25. Slide 25: Recently published OLE data further support Attruby's benefit on ACM and CVH

    Recently published data from the OLE further support Attruby’s statistically significant benefit on ACM and ACM/Recurrent CVH ACM1 ACM/Recurrent CVH2 M30 M36 M30 M36 0% -10% Relative Risk Reduction -20% -30% 25% -40% 36% -50% 42% 46% -60% Attruby resulted in a statistically significant ACM and ACM/R

  26. Slide 26: Attruby Delivers Outstanding Results in Patients with Poor Prognosis

    Looking Ahead: Attruby Delivers Outstanding Results in Patients with Poor Prognosis Natural History ATTRibute-CM mITT Population V122I ATTRv-CM has an aggressive Statistically significant benefit on composite ACM or phenotype and poor prognosis1 first CVH in ATTRv-CM participants vs. placebo2 60 Med

  27. Slide 27: Acoramidis reduced the risk of treatment-emergent adverse events and CVH due to AF

    Acoramidis reduced the risk of both treatment-emergent adverse events and the CVH due to AF-related events irrespective of the history of AF Incidence of CVH due to AF/AFL events* Incidence of new-onset AF/AFL events Occurrence of CVH Frequency of CVH RRR, 33% RRR, 43% RRR, 17% to AF-related events

  28. Slide 28: ACT-EARLY is the first ATTR primary prevention clinical trial

    ACT-EARLY is the first ATTR primary prevention clinical trial, opening a new potential therapeutic paradigm for patients Current therapeutic paradigm: slow the progression of disease in patients with diagnosed ATTR 130+ ATTR Variants ~600 Participants ACT-EARLY is exploring whether acoramidis has th

  29. Slide 29: Elevated TTR levels are associated with improved survival

    Additional data: Elevated TTR levels are associated with improved survival Genetic stabilization of transthyretin associated with Higher TTR concentration associated with improved health outcomes (N≈69K individuals)1 greater life expectancy (N≈102K individuals)2 - WT - T119M Carriers3 Hazard ratio (

  30. Slide 30: Infigratinib

    Infigratinib

  31. Slide 31: Significant unmet need in skeletal dysplasias; a large and rapidly growing market

    There remains a significant unmet need for many children with skeletal dysplasias; this represents a large ($4B+) and rapidly growing market Addressable people by indication in US/EU1 Annualized achondroplasia product sales2 (current population eligible for treatment) ($M WW, annualized by quarter)

  32. Slide 32: Infigratinib is a best-in-class FGFR3 inhibitor

    Infigratinib is a best-in-class FGFR3 inhibitor that targets achondroplasia and hypochondroplasia at their source Mechanism Design Principles FGFR3 FGFR3 Gain-of-function Maximize efficacy by targeting variant disease at the source Infigratinib For all the manifestations of ACH and HCH, (FGFR3 TKI)

  33. Slide 33: At 18 months, infigratinib has shown persistent improvement in AHV and body segmentation

    At 18 months, infigratinib has shown persistent improvement in AHV and body segmentation, along with a favorable safety profile Mean change from baseline in annualized height velocity Upper body to lower body segment ratio (AHV) (Lower value means improved proportionality) +3.38 cm/yr 2.05 +2.51 cm/

  34. Slide 34: Fully enrolled Phase 3 study (PROPEL 3) of infigratinib in Achondroplasia

    We have fully enrolled a Phase 3 study (PROPEL 3) of Infigratinib in Achondroplasia with LPLV in 2H 2025 0.25 mg/kg/day Infigratinib (N ~ 76) Open Label Screening and Extension Observational Period Randomization Children are Children are followed 2:1 followed until for a minimum of 6 (N = 114) adult

  35. Slide 35: Hypochondroplasia is a FGFR3-related skeletal dysplasia

    Hypochondroplasia is a FGFR3-related skeletal dysplasia • Autosomal dominant condition Infigratinib directly targets FGFR3 signaling • Similar incidence to achondroplasia • Greater genetic heterogeneity in FGFR3 pathogenic variants (e.g. N540K in addition to others) • Clinical features: • Moderate d

  36. Slide 36: Hypochondroplasia is a large, mechanistically de-risked expansion opportunity

    Hypochondroplasia is a large, mechanistically de-risked expansion opportunity; FPI recently achieved in Phase 2 study Rationale for infigratinib Recent progress and upcoming milestones Directly targets the underlying cause of hypochondroplasia, FGFR3 overactivity​1,2 Observational run-in study for P

  37. Slide 37: Encaleret

    ~ oO _ 2 © 1S] c Lu

  38. Slide 38: ADH1 is a serious and rare genetic condition with no indicated therapies

    ADH1 is a serious and rare genetic condition for which there are no indicated therapies and diagnosis rates are low An analogous ADH1 market is XLH 12K ADH1 Carriers XLH ADH1 ~12K carriers of ADH1 Prevalence (US) 12K5 12K causing variants in the US Acute hypocalcemia risk, based on 4 population Dise

  39. Slide 39: Encaleret is a first-in-class, disease-modifying therapy for ADH1

    Encaleret is a first-in-class, disease-modifying therapy that targets the underlying disease mechanism of ADH1 Mechanism Design Principles Normal CaSR senses and Encaleret is a CaSR antagonist regulates serum Ca levels to designed to decrease the sensitivity maintain homeostasis of CaSRs to extracel

  40. Slide 40: Phase 2B results showed rapid and sustained normalization of serum Ca, urine Ca, and PTH

    Phase 2B results demonstrated rapid and sustained normalization of serum Ca, urine Ca, and serum PTH, without need for dose escalation Mean responses through 18 months of treatment (N=13) Participants with blood Ca and urine Ca in the target range 11 10 ** 9 Blood cCa (mg/dL) 8 100% 7 6 80% 69% % of

  41. Slide 41: Fully enrolled Phase 3 study (CALIBRATE) of encaleret in ADH1

    We have fully enrolled the Phase 3 study (CALIBRATE) of encaleret in ADH1 and expect topline results in 2H 2025 Screening and SoC Encaleret Optimization Period Encaleret Titration Period (N ~ 47) Maintenance Period • Age > 16 years of age SoC Long-Term • Documented pathogenic Maintenance Extension R

  42. Slide 42: Encaleret could address a broader chronic hypoparathyroidism population

    Encaleret has the potential to address unmet need and provide an oral medicine for a broader chronic hypoparathyroidism population Encaleret potential Chronic Hypoparathyroidism development (~200K in US+EU)1,2,3 opportunity Post-surgical Genetic Autoimmune Idiopathic (65%-75%)4,5 (~12.5%)5 (<10%)5 (

  43. Slide 43: Preliminary data support encaleret as an oral option for chronic hypoparathyroidism

    Preliminary data support the potential for encaleret as an effective oral option for chronic hypoparathyroidism (HP) Ongoing proof-of-principle study of encaleret in post- surgical hypoparathyroidism (PSH) N=7, Preliminary Results • High Unmet Need Current management requires careful balance of bloo

  44. Slide 44: BBP-418

    ie) ei + BBP-

  45. Slide 45: LGMD2I/R9 is a progressive neuromuscular disease with high unmet need

    LGMD2I/R9 is a progressive neuromuscular disease with high unmet need, representing a >$1B market opportunity in the US and EU Addressable patients by indication Unmet need • LGMD2I/R9 is an inherited neuromuscular disorder characterized 9K by lower-limb weakness and loss of ambulation as well as re

  46. Slide 46: BBP-418 is a first-in-class, disease-modifying therapy for LGMD2I/R9

    BBP-418 is a first-in-class, disease-modifying therapy with potential to be the first approved therapy for LGMD2I/R9 Mechanism Design Principles  FKRP glycosylates alpha-dystroglycan (αDG), stabilizing muscle cells by binding extracellular ligands to act as a “shock absorber” for muscle fibers Prov

  47. Slide 47: Increases in glycosylated αDG and stabilization of ambulatory measures in Phase 2

    Significant increases in glycosylated αDG in muscle and stabilization of ambulatory measures were observed in a Phase 2 study of BBP-418 Increase in glycosylated αDG in muscle observed post dosing with BBP-418 (median ± 95% CI) Change from baseline in 10-meter walk test (m/s) L276I/L276I homozygous

  48. Slide 48: Fully enrolled Phase 3 study (FORTIFY) of BBP-418 in LGMD2I/R9

    We have fully enrolled a Phase 3 study (FORTIFY) of BBP-418 in LGMD2I/R9 and expect topline interim analysis data readout in 2H 2025 BBP-418 (N ~ 75) BBP-418 (N ~ 75) Screening Interim Analysis • Genetically Randomization (N ~ 70) Open Label confirmed, 2:1 (N ~ 112) Extension symptomatic Topline Dat

  49. Slide 49: BBP-812

    BBP-812

  50. Slide 50: Canavan disease is a severe, fatal, ultra-rare pediatric disease

    Canavan disease is a severe, fatal, and ultra-rare neurodegenerative pediatric disease with no approved therapies Unmet need • Canavan is an ultra-rare neurodegenerative disease with ~1,000 patients across the US and EU • Canavan is usually fatal within the first two decades of life, and >25% of pat

  51. Slide 51: BBP-812 is a first-in-class, disease-modifying therapy for Canavan disease

    BBP-812 is a first-in-class, disease-modifying therapy that targets Canavan disease directly at its source Mechanism Design Principles Provide first disease-modifying therapy Target the condition directly at the source, utilize single registrational study & biomarker for accelerated approval Provide

  52. Slide 52: Sustained reductions in NAA levels and improved motor function after 12 months

    Significant, sustained reductions in NAA levels and improvement in motor function after 12-months of BBP-812 dosing in Phase 1/2 study Urine N-acetylaspartic acid (NAA) levels Hammersmith Infant Neurological Examination (HINE-2) Trajectory Change in HINE-2 Total Score Months since Baseline Natural B

  53. Slide 53: BridgeBio Ecosystem Highlights

    BridgeBio Ecosystem Highlights

  54. Slide 54: BBOT has progressed two first-in-class molecules into the clinic

    BBOT has progressed two potentially first-in-class molecules into the clinic with a third expected in 1H 2025 Program Mechanism of Action Status • First direct inhibitor of KRASG12C ON BBO-8520 • Inhibits both KRASG12C GTP (active) and GDP (inactive) states Enrolling KRASG12C ON / OFF • Differentiat

  55. Slide 55: The GondolaBio pipeline features a diverse set of programs

    The GondolaBio pipeline features a diverse set of programs across therapeutic areas and modalities Lead IND Est. Patient Pop. Indication Discovery Phase 1 Optimization Enabling (US + EU) Erythropoietic Protoporphyria (EPP) 20k Galactosemia 10k Alpha-1 Antitrypsin Deficiency (AATD) 200k Neurofibromat

  56. Slide 56: About Attruby and BridgeBio

    About Attruby (acoramidis) Attruby is the only near-complete (≥90%) stabilizer of Transthyretin (TTR) approved in the U.S. for the treatment of adult patients with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. Attruby was generally well-tolerated. The most common

BridgeBio Pharma — Investor Presentation (April 2025) on 6ix